Healx and Ovid Therapeutics to enter strategic partnership for gaboxadol.
Ovid Therapeutics and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, announced that Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol.
Under the agreement, Healx plans to investigate the compound as part of a potential combination therapy for Fragile X syndrome, as well as a treatment for other indications.
Gaboxadol has previously been tested as a monotherapy for Fragile X syndrome in a Phase IIa clinical study by Ovid. Healx will now seek to find an optimal treatment for the condition by combining gaboxadol with other compounds, including HLX-0201, that have been identified by the company’s proprietary AI platform, Healnet.
Alongside the initial focus on Fragile X syndrome, Healx plans to use its cutting-edge indication expansion technology to identify other conditions that could also be treated by gaboxadol.
Should Healx exercise its option, Ovid will receive milestone payments for specific clinical, regulatory, and commercial achievements associated with gaboxadol’s development. Additionally, Healx will pay Ovid tiered royalties on net sales associated with marketed therapies containing gaboxadol. Ovid will retain the option to become Healx’s co-development and co-commercialization partner and will share net profits and losses in lieu of the milestones and royalty payments. Ovid does not plan to conduct further trials with gaboxadol..
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.